(SRDX) Surmodics Inks Licensing Deal With Roche

October 9th, 2009

On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device combination products in chosen markets.

Under the terms of the agreement, SurModics is entitled to an up-front payment of $3.5 million. Furthermore, the deal could be worth up to $200 million in delayed payments if multiple products are successfully developed. SurModics will also receive royalties on product sales. SurModics will receive payments for its development services. Under the terms of the agreement, Roche and Genentech have the right to obtain manufacturing services from SurModics.

The transaction provides Roche and Genentech complete access to the biodegradable microparticles developed by SurModics. They intend to use the products in a long-lasting version of their optical drug Lucentis (ranibizumab injection), a prescription medicine approved for treating patients with wet age-related macular degeneration.

Lucentis, discovered by Genentech, is being co-developed with Novartis Ophthalmics Business Unit for eye related diseases or disorders. Genentech has commercial rights in the United States and Novartis (NVS) for the rest of the world.

We believe the deal provides further opportunities to Roche, one of the world’s biggest drugmakers, and Genentech, which was acquired in 2008, to develop additional compounds for the treatment of ophthalmic diseases. This will broaden the treatment opportunities for patients suffering from eye diseases.

The news had a positive effect on SurModics and its shares rose by over 19%, closing Tuesday at $29.04.

SurModics, which provides surface modification and drug delivery technologies to medical device and pharmaceutical companies, competes mainly with Angiotech Pharmaceuticals Inc. (ANPI).

Zacks Investment Research
View original at: Zacks.com News Feed

More on this topic (What's this?)
H1N1: Canada Issues Warning Over Tamiflu (Shocked Investor, 9/26/09)
Tamiflu Resistance and The Fall of H1N1 Drug Companies (Shocked Investor, 12/14/09)
NNVC (All Allan, 11/20/09)
The Impact of the Genome (Contrarian Profits, 8/18/09)
Read more on SurModics, Roche Pharmaceuticals at Wikinvest


Similar Posts: | | | | | | Diagnostic Substances | Healthcare

RSS feeds: Angiotech Pharmaceuticals Inc | ANPI | Novartis AG | NVS | SRDX | SurModics Inc. | Diagnostic Substances | Healthcare |

Other Posts by vitalstocks | RSS Feed for this author

Post a Response

You must be logged in to post a comment.